In vivo neutron activation analysis for bone calcium (INVAA) in malignant hyperthermia susceptible patients. 1979

B A Britt, and J E Harrison, and K G McNeill

Some non-rigid Malignant Hyperthermia Susceptible (MHS) patients have a greater than normal incidence of fractures. Radiologically their long bones are slightly thinner than normal. Excessive numbers of caries because of thin dental enamel may also be present. The Malignant Hyperthermic (MH) defects thus appears to involve cells of bone appendages as well as of muscle. We have measured the concentration of calcium in bone by neutron activation analysis and have found it to be reduced in both non-rigid and rigid malignant hyperthermia susceptible patients. The reductions were particularly marked for the non-rigid patients. Bone calcium concentrations were lower in males than in females and in those under 16 and over 60 years of age. This is additional evidence is favour of the hypothesis that malignant hyperthermia is a widespread defect affecting tissues and organs throughout the body.

UI MeSH Term Description Entries
D008297 Male Males
D008305 Malignant Hyperthermia Rapid and excessive rise of temperature accompanied by muscular rigidity following general anesthesia. Hyperpyrexia, Malignant,Hyperthermia, Malignant,Malignant Hyperpyrexia,Anesthesia Related Hyperthermia,Hyperthermia of Anesthesia,Anesthesia Hyperthermia,Hyperthermia, Anesthesia Related,Malignant Hyperpyrexias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D009501 Neutron Activation Analysis Activation analysis in which the specimen is bombarded with neutrons. Identification is made by measuring the resulting radioisotopes. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Activation Analysis, Neutron,Analysis, Neutron Activation,Activation Analyses, Neutron,Analyses, Neutron Activation,Neutron Activation Analyses
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D005260 Female Females
D006221 Halothane A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. NITROUS OXIDE is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) 1,1,1-Trifluoro-2-Chloro-2-Bromoethane,Fluothane,Ftorotan,Narcotan

Related Publications

B A Britt, and J E Harrison, and K G McNeill
July 1973, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
B A Britt, and J E Harrison, and K G McNeill
October 2013, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
B A Britt, and J E Harrison, and K G McNeill
March 1990, British journal of anaesthesia,
B A Britt, and J E Harrison, and K G McNeill
January 1990, Acta anaesthesiologica Belgica,
B A Britt, and J E Harrison, and K G McNeill
March 1970, The International journal of applied radiation and isotopes,
B A Britt, and J E Harrison, and K G McNeill
January 1979, Physics in medicine and biology,
B A Britt, and J E Harrison, and K G McNeill
March 1999, Hiroshima journal of medical sciences,
B A Britt, and J E Harrison, and K G McNeill
January 1988, Acta anaesthesiologica Belgica,
B A Britt, and J E Harrison, and K G McNeill
January 1985, Acta cientifica venezolana,
B A Britt, and J E Harrison, and K G McNeill
October 2013, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
Copied contents to your clipboard!